This can be explained by the fact that HF management and coronary disease require distinct therapeutic strategies [24, 25], and finerenone's primary action on the mineralocorticoid receptor may not address the underlying atherosclerotic processes that drive MI [26, 27]. This evidence concerns the gene NR3C2 and hydrops fetalis.